Systemic effects after intravitreal injection of bevacizumab in new born rabbit eyes

References

• Freeman WR. Practical atlas of retinal disease and therapy. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1998:325–344.
   Google Scholar
• Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome–structure and function. Arch Ophthalmol 1990;108:1408–1416.
   PubMedGoogle Scholar
• Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–1694.
   PubMed Web of Science ®Google Scholar
• Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126:1161–1163.
   PubMedGoogle Scholar
• Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450–1455.
   PubMed Web of Science ®Google Scholar
• Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727–1730.
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, et al. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19–S25.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kuffel RR Jr., Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008;28:831–838.
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 2007;38:233–237.
   PubMedGoogle Scholar
• Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13–S18.
   PubMed Web of Science ®Google Scholar
• Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6–10.
   PubMed Web of Science ®Google Scholar
• Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina (Philadelphia, Pa) 2006;26:257–261.
   PubMed Web of Science ®Google Scholar
• Wu WC, Lai CC, Chen KJ, et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 2010;51:3701–3708.
   PubMed Web of Science ®Google Scholar
• Nagai T, Sato M, Kutsuna T, et al. Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair. Arthritis Res Ther 2010;12:R178.
   PubMed Web of Science ®Google Scholar
• Wu WC, Yeh PT, Chen SN, et al. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011;118:176–183.
   PubMed Web of Science ®Google Scholar
• Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol 2013;155:150–158 e151.
   PubMed Web of Science ®Google Scholar
• Raizada S, Al Kandari J, Al Foudari A. Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Middle East Afr J Ophthalmol 2011;18:196–197.
   PubMedGoogle Scholar
• Roohipoor R, Ghasemi H, Ghassemi F, et al. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Graefes Arch Clin Exp Ophthalmol 2011;249:1295–1301.
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Snir M, Ron Y, et al. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity. Retina (Philadelphia, Pa.) 2011;31:1239–1247.
   PubMed Web of Science ®Google Scholar
• Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:319. author reply 320.
   PubMedGoogle Scholar
• Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr 2009;21:182–187.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603–615.
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327–333 e321.
   PubMed Web of Science ®Google Scholar
• Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010;51:1606–1608.
   PubMed Web of Science ®Google Scholar
• Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011;31:161–168.
   PubMed Web of Science ®Google Scholar
• Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 2015;133:391–397.
   PubMed Web of Science ®Google Scholar
• Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina (Philadelphia, Pa) 2017;37:694–701.
   PubMed Web of Science ®Google Scholar
• Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatr 2011;100:1523–1527.
   PubMed Web of Science ®Google Scholar
• Quinn GE, Darlow BA. Concerns for development after bevacizumab treatment of ROP. Pediatrics 2016;137: e20160057.
   PubMed Web of Science ®Google Scholar
• Lien R, Yu MH, Hsu KH, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One 2016;11:e0148019.
   PubMed Web of Science ®Google Scholar
• Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016;137:pii: e20153218.
   PubMed Web of Science ®Google Scholar
• Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011;31:1877–1884.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Muether PS, Stratmann NK, et al. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors. Retina 2015;35:69–74.
   PubMed Web of Science ®Google Scholar
• Meyer CH, Krohne TU, Holz FG. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 2012;90:68–70.
   PubMed Web of Science ®Google Scholar
• Ligi I, Boubred F, Grandvuillemin I, Simeoni U. The neonatal kidney: implications for drug metabolism and elimination. Curr Drug Metab 2013;14:174–177.
   PubMed Web of Science ®Google Scholar
• Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992;114:521–532.
   PubMed Web of Science ®Google Scholar
• Sakowski SA, Heavener SB, Lunn JS, et al. Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression. Gene Ther 2009;16:1292–1299.
   PubMed Web of Science ®Google Scholar
• Falk T, Zhang S, Sherman SJ. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol Neurodegener 2009;4:49.
   PubMed Web of Science ®Google Scholar
• Been JV, Zoer B, Kloosterboer N, et al. Pulmonary vascular endothelial growth factor expression and disaturated phospholipid content in a chicken model of hypoxia-induced fetal growth restriction. Neonatology 2010;97:183–189.
   PubMed Web of Science ®Google Scholar
• Zisa D, Shabbir A, Suzuki G, Lee T. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochem Biophys Res Commun 2009;390:834–838.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao T, Huang W, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells 2009;27:3021–3031.
   PubMed Web of Science ®Google Scholar
• Ishii M, Tanaka E, Imaizumi T, et al. Local VEGF administration enhances healing of colonic anastomoses in a rabbit model. Eur Surg Res 2009;42:249–257.
   PubMed Web of Science ®Google Scholar
• Yamamoto C, Yagi S, Hori T, et al. Significance of portal venous VEGF during liver regeneration after hepatectomy. J Surg Res 2010;159:e37–e43.
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795–803.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611.
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–1309.
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242–248.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–4380.
   PubMed Web of Science ®Google Scholar
• Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009;116:2165–2169.
   PubMed Web of Science ®Google Scholar
• Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009;116:1599–1603.
   PubMed Web of Science ®Google Scholar
• Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008;49:5177–5182.
   PubMed Web of Science ®Google Scholar
• Arriaga Y, Becerra CR. Adverse effects of bevacizumab and their management in solid tumors. Support Cancer Ther 2006;3:247–250.
   PubMedGoogle Scholar
• Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009;66:999–1013.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855–859.
   PubMed Web of Science ®Google Scholar
• Campbell RJ, Gill SS, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case–control study. BMJ 2012;345:e4203.
   PubMed Web of Science ®Google Scholar
• Bonfanti L, Ponti G. Adult mammalian neurogenesis and the New Zealand white rabbit. Vet J 2008;175:310–331.
   PubMed Web of Science ®Google Scholar
• Ponti G, Crociara P, Armentano M, Bonfanti L. Adult neurogenesis without germinal layers: the “atypical” cerebellum of rabbits. Arch Ital Biol 2010;148:147–158.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.
   PubMed Web of Science ®Google Scholar
• Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008;49:522–527.
   PubMed Web of Science ®Google Scholar